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Abstract
The paper begins with an introduction of the new trends of pharmaceutical marketing focusing on
the role of relationship marketing. Then it gives a short overview about the theoretical background
of relationship marketing. It matches the different relationship marketing theories, and investigates
the relationships in the pharmaceutical market focusing on the Hungarian hospital market. The paper
reports about an empirical study of hospitals’ drug procurement in Hungary. The results support the
improvement of the relationship marketing activity of pharmaceutical companies.
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1. Introduction
The new trends of pharmaceutical marketing are effected by the trends of the phar-
maceutical industry itself. The number of new innovative drugs is less and less in
connection with the increasing R&Dcosts (SZALKAI et al., [14]). The development
cost of a new drug (including the research cost of the unsuccessful substances) is
around 800 million USD (DIMASI et al., [5]). According to industry experts, R&D
is no longer the industry’s driving force for growth (BROWN, [2]). Even if the new
drug is more effective and has less side effect (this is the pivotal element of drugs’
quality) than the other ones available in the market that is not the only factor which
determines its success. To remain profitable, for a drug producer, developing its
marketing activity may be the key of success.
Nowadays, more than 60% of the marketing costs of pharmaceutical enter-
prises account for the communication with physicians (HARMS et al., [8]). The
role of physicians in deciding the therapy is still dominant, but in some areas (OTC
market, patient groups) patients have more and more power to choose between the
products. Other important target customers are the pharmacists, hospitals, whole-
salers, governmental forces, etc. Governments try to stop the rapidly growing med-
ical expenditures, so affordable drugs have competitive advantage over the ‘only’
effective drugs. In the USA for example a price comparison website is planned
to be launched to give information about drug prices (SCRIP, [12]). Under the
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pressure of these new challenges pharmaceutical marketing has to focus not only
on the traditional target customers (physicians, patients), but on other customers,
stakeholders as well, already in the development phase of a new drug. Pharmaceu-
tical marketing has become a multidimensional task, which integrates Key Account
Management, Service Marketing, Economical Marketing and Political Marketing
(HARMS et al., [8]) in order to be sure that the new product will be successful.
It contributes to the actuality of the topic, that not only in the pharmaceutical
market, but generally the capital of partnership becomes more valuable.
2. Relationship Marketing Theories in Brief
In themarketing literature relationship marketing became popular in the 1990s. The
term relationship marketing has different meanings and it has continuously changed
over the years. According to MÖLLER et al. [10] there is no developed theory of
relationship marketing, only a variety of descriptions and of theories exists, so it is
not considered to be a discipline yet. In a narrow interpretation it is very close to
database marketing or aftermarketing, where its basic goal is customer retention.
In a broader term relationship marketing is more strategic: instead of manipulating
the customers they are involved into the relationship (PARVATIYAR et al., [11]).
This strategic way of thinking is in connection with the newest marketing concepts,
namely that the enterprises should focus more on their customer portfolio instead
of on their product portfolio (KOTLER et al., [9]).
The different approaches of relationshipmarketing can be classified according
to different aspects:
1. Themost obvious difference between the theories is the placewhere theywere
born: in the USA or in Europe. The different ways of thinking derives from
the different buying behaviour of organizations. One of the most significant
representative of the European school is the IMP (Industrial Marketing and
Purchasing) Group.
2. Experts distinguish 3 levels of relationship marketing. On the concept level
researches are made mostly about the measurement of relationship’s per-
formance. On the model level investigation goes down to the depth of the
relationship, researchers try to answer the question how the relationships
work. Examples for this model level approach are the interaction model, or
the key account management model. According to the third approach re-
lationship marketing is about developing and managing successful relation-
ship marketing programs. The relationship marketing process consists of
four subprocesses: formation process, management and governance process,
performance evaluation process, and relationship evolution or enhancement
process (PARVATIYAR et al., [11])
3. There are theories on the basis of the parties in the supply chain involved in
the relationship. Relationships can be examined between buyer and seller (it
is the case most often analysed), or buyer and buyer, or seller and seller, etc.
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4. On the basis of the exchange characteristics a big variety of theories exists.
According to the customer type we can distinguish between consumer rela-
tionships and interorganizational relationships (MÖLLER et al., [10]). Nowa-
days – thanks to thinking in networks – relationships can be analysed not only
between two parties, but as partnerships in a network of enterprises. Inter-
activity can also be an aspect of relationships. In early studies active seller
and inactive buyer were in the focus of the studies, interactive relationships
have even more specialities to examine. In consideration of the dimension
of time the characteristics of the relationships differ, if it is a short term or a
long term relationship.
The overall purpose of relationship marketing is to improve marketing pro-
ductivity and enhance mutual value for the parties involved in the relationship
(PARVATIYAR et al., [11]). Experts of the IMP Group identified three different
types of relationship marketing programs: continuity marketing, one-to-one mar-
keting, and partnering programs. The basic aim of continuity marketing programs is
to retain customers and increase loyalty (Bhattacharya, 1998* cit in PARVATIYAR,
[11]). One-to-one marketing programs are aimed at meeting and satisfying each
customer’s needs uniquely and individually. Partnering programs involve partner-
ing relationships between customers and marketers to serve end-user needs. Table 1
collects the program types which can be imagined according to the customer type.
Table 1. Types of relationship marketing programs
Customer Type
Program Type
Individual
Consumers
Distributors/
Resellers
Institutional Buyers
(Business to Business)
Continuity marketing loyalty programs
continuous
replenishment and
ECR  programs
special supply
arrangements
(e.g., JIT)
Individual marketing
data warehousing
and data mining
customer business
development
key account
management
Comarketing/
partnering
cobranding
cooperative
marketing
joint marketing and
codevelopment
Source: PARVATIYAR [11], p. 19.
 ECR = efficient consumer response
In the next two sections we will focus on two relationship models which are
relevant in relation with the pharmaceutical market.
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2.1. The Interaction Model of Buyer-Seller Relationships
In the interaction model the relationship of two organizations – the buyer and the
seller – is analysed. According to this model (Fig. 1) the relationship corresponds
to series of interactions between the parties.
Product Characteristics
Industry Company Individuals 
Buyer’s characteristics 
Individuals Company Industry 
Supplier’s characteristics 
Interaction mechanisms
Information exchange 
Conflict resolution 
Adaptations
Personal contact patterns 
Interaction atmosphere 
Closeness, commitment, trust 
Buyer’s 
interaction
strategy
Competitive 
Cooperative 
Command 
Supplier’s 
interaction
strategy
Competitive 
Cooperative 
Command 
Interaction process 
Fig. 1. Interactionmodel of buyer-seller relationship (Source: simplified scheme of CAMP-
BELL [4], p. 268.)
The interaction model is based on the following statements (Ford, [6]):
1. Both buyers and sellers are active participants in the market, both of them
make efforts to find the suitable partner in order to achieve their goals.
2. These relationships are long term, close and involving a complex pattern of
interactions between and within each organization. It is more than a simple
sale or purchase.
3. The links between buyer and seller often become institutionalized into a set
of roles that each party expects the other to perform. Adaptations often
occur when one of the parties makes modification in the product, in financial
arrangements, or in inventory routines, etc.
4. The interaction model assumes continuous supply of the products.
The whole interaction process is embedded in the interaction environment.
The environment has several aspects, like the market structure, dynamism, inter-
nationalization, position in the manufacturing channel, the social system (FORD,
[?]). In the business market the buyer’s involvement in the product development
process has also an effect on the interaction. In the pharmaceutical market the mar-
ket characteristics (strict regulations) and the product’s special characteristics have
dominant impact on the relationships.
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2.2. The Key Account Management  KAM Model
The key account management model is based on the customer portfolio of the
enterprise. A very detailed overview about the customer portfolio is presented by
FORD [7]. He distinguishes 9 groups of customer relationships according to their
contribution to the company’s success, according to the risks laid in them, to the
needed resources and to their impacts on the other relationships of the firm. The
enterprise should make decisions about the strategic importance of each customer.
Strategic importance of customers can be determined using sales volume,
future potential, prestige, etc. (FIOCCA, 1982* cit inCANNON et al, [3]). According
to CESPEDES (1995* cit in CANNON et al., [3]) key account is a customer who ‘(a)
purchases a significant volume as a percentage of a seller’s total sales, (b) involves
several people in the purchasing process, (c) buys for a geographically dispersed
organization, and (d) expects special attention such as logistical support, inventory
management, price discounts, and customized applications’. Others define key
accounts as ‘customers that have strategic importance to the seller, purchase a large
volume from the seller, and have the potential to lower the seller’s costs’ (KRAPFEL
et al., 1991* cit in CANNON et al., [3]). These numerous characteristics can lead
to different approaches of key customers.
3. Relationship Marketing in the Pharmaceutical Market
In this paper we discuss relationships with two very important participants in the
pharmaceutical market. First the physicians then for a closer look the hospitals will
be analysed from the marketing point of view.
3.1. Physicians as Customers
As it was mentioned in the introduction part, physicians are the most important
target customers for the pharmaceutical enterprises. Compared to the traditional
marketing concept, physicians are not the end consumers of the products, but their
role is more important than that of the patients, because in most of the cases they
induce the demand of drugs. For this reason relationship marketing should be
analysed toward this target group.
In this case the definition of key customer changes: we can not talk about exact
sales, but the initiators of sales. Sometimes the target customer is not the physician
who writes prescriptions, but the opinion leaders who influence their colleagues to
do so (TSANG, [15]). Nowadays to reveal the prescription behaviour of physicians
is the key task for the pharmaceutical companies. The data about the prescriptions
from the past and the information about the wants, needs, motivations of the practice
can become a competitive advantage for the company that understands how to use
it in driving their marketing efforts (VANDERVEER, [16]). Pharmaceutical sales
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and marketing analysts realized that the success of a brand depends mostly on the
prescribing behaviour (change to another brand) of the physician (BARNES, [1]).
Monitoring the prescribing practice of each physician needs a suitable technology
for the companies.
All these pieces of informations correspond to individual marketing programs
(see Table 1) as relationship marketing activity of pharmaceutical companies. In
the case of physicians as individual customers, data warehousing and data mining
are noted as suitable methods and also the practice of companies supports these
methods.
3.2. Hospitals as Customers
For the investigation of the relationship with hospitals I highlight the topic under
the circumstances of Hungary.
In the case of hospitals the performance of relationship marketing is mea-
surable directly through the drug procurement of the institution. According to the
marketing theory, customer relationships are to a large extent determined by the
buying behaviour of the customers to a large extent (FORD, [6]).
Generally, the relationship between drug producers and hospitals is effected
by the followings:
1. Hospitals have a key role in the drug development process, taking part in the
clinical trials of new drugs and in other tests.
2. Hospitals considered to be the place of the introduction stage of drugs’ life
cycle, so the success of a new drug in the total pharmaceutical market will
be effected much by the sales toward hospitals.
3. Pharmaceutical sales in pharmacies are often induced by the hospitals in the
case of prescription drugs, since family doctors usually prescribe the brand,
which was taken by the patient during his/her therapy in the hospital.
4. In case of physicians who work in hospitals and have special surgery hours,
their prescription behaviour is influenced by the selection of drugs in the
hospital.
5. Since the opinion leaders work in hospitals, hospitals are suitable for image
building of a medicine or a producer.
6. Postmarketing studies (analysis with the medicine after a certain period it was
launched into the market, for example in order to reveal the incidental side
effect) take place also in the hospitals whereby the awareness of the brand
can be sustainable and the sales may increase.
Looking at the statements above, hospitals considered to be a strategic market
for drug producers. Compared to this strategic role, regarding the sales volume in
hospitals and in pharmacies in Hungary, it can be established, that only 15% of the
sales go to the hospitals (MAGYOSZ).
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Since in Hungary the hospitals purchase 80% of their drug consumption
from wholesalers and only 20% directly from the drug producers, the relationship
between hospitals and wholesalers also needs to be investigated. The relation-
ship between the hospitals and the wholesalers is determined by the followings
(SZABÓ, [13]):
1. In the hospitals the selection of drugs is wider than in the pharmacies.
2. The drugs used in hospitals are more expensive.
3. The shipping cost is lower in the hospitals.
4. Forecasting the sales in hospitals is unsure.
5. Hospitals have lower buying power than pharmacies do.
These characteristics of hospitals lead to a relatively unstable market for
pharmaceutical wholesalers. Fig. 2 presents the relationships in the hospital market.
Drug Producer Hospital
Wholesaler
Representative 
KAM
Representative 
Key account physicians 
Chief pharmacist 
Financial director 
Director-general 
Buying 
center
Interface
Interface
Interface
Fig. 2. Buyer-seller relationships in the hospital market – the Hungarian case
Buyers and sellers are active participants of the relationship. Reverse market-
ing (when the buyer sets up the purchasing conditions) often occurs in this market,
in most cases the price conditions are in the focus: hospitals try to cut prices be-
cause of their low budget. Considering the order routines, weekly or daily orders
are widespread, depending on the urgent need of medicines or the shipping contract.
As a feedback to the marketing theories, these characteristics of the pharmaceutical
relationships make the interaction approach adaptable to the further analysis of this
special market.
In case of the hospital market key account management is used as a rela-
tionship marketing program which refers to the data presented in Table 1. The
constitution of the buying center depends among others on the organization specific
factors and personal characteristics. Accordingly, hospitals should be taken into
account as customers with individual needs, and mass customization is the suitable
marketing strategy toward hospitals.
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4. Drug Purchase of Hospitals in Hungary – an Empirical Study
The survey introduced here is a part of a study made for my PhD work. Only the
research results are presented here, which are in close relation with the topic of this
paper. The results are applied to (1) the influencing factors concerning hospitals’
drug procurement, to (2) the evaluation of the relationships with the suppliers, to
(3) the information sources of a new drug, to (4) the motivation for tryout and use
of new drugs.
The surveywas conducted inNov –Dec 2002 among the hospitals inHungary.
The research method was mail questionnaire, the sample contained 152 hospitals.
Finally, 65 chief pharmacists and 48 lead physicians took part in the study. The
responses were representative concerning geography, ownership and hospital size.
The major results of the survey are presented briefly in the next section
5. Results and Discussion
According to the responses of the chief pharmacists, financial factors – price and
discounts – are the most convincing at the drug procurement. At the third place, the
physician’s influence in the decision process was marked (Fig. 3). The influencing
effect of the producers’ promotion on drug procurement brought the most hetero-
geneous results, the same number of respondents indicated this factor as important,
or not important and less important factor.
1 2 3 4 5
P rice
D iscount
P hys ic ian's  inf luence  on purchase
Innovative  vs . generic  d rug
P roducers ' p rom otion
R e tail p rice
P ub lic  f inanc ing
Fig. 3. Influencing factors of drug purchase determined by the chief pharmacist (on scale
1-5)
In each hospital the chief pharmacist was asked to evaluate the relationship
with the major drug supplier (in most of the cases they are wholesalers). The results
are shown inFig. 4. More than a half of the respondents gave 5 (on a scale 1-5, where
5 means the most adequate characteristic) for trust and stability in the relationship.
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These two factors are the ones which occur the most often in the relationship mar-
keting literature as determining elements in the business relationships. The role of
former experiences and the continuity were also significant characteristics of the
relationship. The respondents gave very distinct opinions about the role of personal
bonds in the relationship. As many pharmacists valued this factor not typical at all
as typical, and the modus were around 3. Concerning the total satisfaction, most of
the respondents were satisfied with the drug suppliers.
1 2 3 4 5
Routinish relationship
Satisfactory relationship
Stability
Trust
Former experiences
Continuity
Personal bonds
Total satisfaction
Fig. 4. Evaluation of the relationship with the major supplier by the chief pharmacist (on
scale 1-5)
Investigating the information sources of new – innovative1 and generics2 –
drugs, most of the pharmacists and the physicians indicated the producer’s repre-
sentatives (Table 2 and Table 3). In case of generics direct mail was mentioned
several times, and the role of the pharmacist can be established in informing the
physician about the generic drugs.
Most of the asked physicians (36 out of 41) are willing to try out new drugs
because they read about them in the literature. The majority of the respondents (23
physicians) found it mostly motivating if the drug has new therapeutic advantage
over others. On average (2,95) the physicians valued least of all the producers’
promotion in the motivation (Fig. 5).
According to the study, the higher effectiveness of a new drug is the primary
factor for applying a new drug in the therapy (Fig. 6). 24 out of 34 physicians think
that producer’s reputation is moderately important or preferably not important when
he/she changes to a new drug.
1Innovative drugs are produced for the first time, they are patent protected.
2Generics drugs are the medicines which are produced after the patent expires.
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Table 2. Information source of new innovative drugs
Pharmacist (number of mention) Physician (number of mention)
Producer’s representative 61 Producer’s representative 32
Literature 45 Literature 33
Conference 34 Conference 22
Direct mail 31 Direct mail 13
Wholesaler’s representative 8 Pharmacist 8
Physician 3 Colleagues 6
Internet 2 Drug database 1
Postgraduate course 1
Electronic database 1
Table 3. Information source of new generic drugs
Pharmacist (number of mention) Physician (number of mention)
Producer’s representative 61 Producer’s representative 37
Literature 33 Literature 10
Conference 23 Conference 9
Direct mail 40 Direct mail 18
Wholesaler’s representative 7 Pharmacist 15
Physician 1 Colleagues 3
Internet 1 Drug database 1
Electronic database 1
6. Summary
The paper is dealing with the investigation of relationship marketing in the phar-
maceutical industry focusing on the relationship with hospitals. It introduces the
new challenges of pharmaceutical marketing and the major aspects of relationship
marketing theories particularly on the basis of the work of the IMP Group.
It reports about the relationships in the Hungarian hospital market, and lists
the determining factors of these relationships. Comparing the theoretical models
with the buyer-seller relationship in the pharmaceutical industry, interactions can
be identified between the drug suppliers and the hospitals. Toward physicians, key
account management model is proved as essential.
The paper briefly introduces a survey about drug procurement of hospitals
in Hungary. It emphasizes the dominant role of price and discounts as influencing
factors. The survey also supports the importance of drug producers’ representatives
in informing the physicians and pharmacists – the two major participants in the
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1 2 3 4 5
Producers' representatives
Experiences of colleagues
Sample
Conference
Literature
Involvement in clinical test
New therapeutic advantage
Fig. 5. Source of motivation to try out new drugs (on scale 1-5)
1 2 3 4 5
Higher effectiveness
Fewer side effects
Comfortable dosage
Comfortable mode of action in body
Own experience
Producer's reputation
Fig. 6. Motive of regular usage of new drugs (on scale 1-5)
buying center – about new drugs. In spite of this, the results show that the physicians
minimize the role of the representative in the tryout of new drug. Due to the small
number of cases in the survey the results can not be generalized, but they indicate
somehow the motive for trying out and applying new drugs. According to the chief
pharmacists the need of hospitals for drugs in Hungary is basically fulfilled, the
relationship with the major supplier can be characterized with stability and trust.
The study can be considered as a start up to similar investigations, since the
hospital market is a quite neglected area of the pharmaceutical marketing literature.
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